Clinical Trials Sponsored by Guiyang Public Health Clinical Center

Total 6193 results

National Cancer Institute (NCI)

Completed

High-Risk Breast Duct Epithelium

Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Prostvac in Patients With Biochemically Recurrent Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer

Prostate Neoplasms | Prostate Specific Antigens

United States
National Cancer Institute (NCI)

Completed

EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma

Mantle Cell Lymphoma | Lymphoma, Mantle Cell

United States
National Cancer Institute (NCI)

Completed

M7824 in People With Recurrent Respiratory Papillomatosis

Human Papilloma Virus | Recurrent Respiratory Papillomatosis | Laryngeal Papilloma, Recurrent | Respiratory Papillomatosis

United States
National Cancer Institute (NCI)

Terminated

Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer

Thyroid Cancer | Low-risk Papillary Thyroid Cancer | Endocrine Malignancy

United States
National Cancer Institute (NCI)

Terminated

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer

Breast Cancer | Ovarian Cancer | Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Optimal Methods of Disease Detection in Children and Young Adults With Acute Lymphoblastic Leukemia in the Pediatric Oncology Branch

Leukemia, Lymphoblastic, Acute | ALL, Childhood

United States
National Cancer Institute (NCI)

Completed

Clinical and Laboratory Analysis of Familial Cancer

Cancer

United States
National Cancer Institute (NCI)

Terminated

Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

Neoplasms, Germ Cell and Embryonal | Lung Neoplasms | Esophageal Neoplasms | Thymus Neoplasms | Mesothelioma

United States
National Cancer Institute (NCI)

Terminated

Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia

Leukemia | Chronic | Lymphocytic | B-Cell

United States
National Cancer Institute (NCI)

Completed

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

Neoplasms

United States
National Cancer Institute (NCI)

Terminated

Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With Gastrointestinal Cancers

Stomach Cancer | Pancreatic Cancer | Esophageal Cancer

United States
National Cancer Institute (NCI)

Completed

MR Image Guided Therapy in Prostate Cancer

Prostatic Neoplasms | Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma

AIDS Related Lymphoma | AIDS-Associated Lymphoma

United States
National Cancer Institute (NCI)

Terminated

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Hormone Receptor Negative Breast Cancer | HER2+ Breast Cancer

United States
National Cancer Institute (NCI)

Completed

A Prospective Study of Diet and Cancer in Members of the American Association of Retired Persons

Cancer | Death

United States
National Cancer Institute (NCI)

Completed

Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas

High Grade Glioma | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine Glioma

United States
National Cancer Institute (NCI)

Terminated

Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004

Colorectal Neoplasms | Colorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Colorectal Adenocarcinoma

United States
National Cancer Institute (NCI)

Terminated

E7 TCR T Cell Induction Immunotherapy for Stage IIB-IVA Cervical Cancer

Uterine Cervical Neoplasms

United States
National Cancer Institute (NCI)

Terminated

Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy

Melanoma | Breast Cancer | Pancreatic Cancer | Lung Cancer | Gastrointestinal Cancers

United States
National Cancer Institute (NCI)

Completed

AZD1775 for Advanced Solid Tumors

Solid Tumors

United States
National Cancer Institute (NCI)

Terminated

Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Chile Biliary Longitudinal Study

Gallbladder Cancer | Nutritional and Metabolic Diseases

Chile
National Cancer Institute (NCI)

Terminated

18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma

Lymphoma

United States
National Cancer Institute (NCI)

Completed

Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer

Medullary Thyroid Cancer (MTC)

United States
National Cancer Institute (NCI)

Completed

Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)

Breast Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Tumors (Others)

United States
National Cancer Institute (NCI)

Completed

Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States
National Cancer Institute (NCI)

Completed

Case-Control Study of Inflammatory Breast Cancer in North Africa

Diabetes

Egypt, Tunisia, Morocco
National Cancer Institute (NCI)

Completed

Long-Term Stability of Oral Microbiome Samples

Oral Microbiota | Long Term Sample Stability

United States
National Cancer Institute (NCI)

Completed

Stomach and Esophageal Cancers in Northern Iran

Esophageal Cancer

Iran, Islamic Republic of
National Cancer Institute (NCI)

Completed

Evaluation of the Sensitivity of Endoscopy to Detect Nasopharyngeal Carcinoma (NPC) in an Epstein-Barr Virus (EBV)-Based NPC Screening Project in China

Nasopharyngeal Cancinoma (NPC)

China
National Cancer Institute (NCI)

Completed

Study of Lymphoma in Asia

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Leukemia | Hodgkin Lymphoma | Multiple Myleoma | Lympocytic, Follicular

China, Hong Kong, Taiwan
National Cancer Institute (NCI)

Completed

Study of Variation Over Time in the Oral Microbiome

Oral Health | Microbiota | Body Mass Index

United States
National Cancer Institute (NCI)

Completed

Cancer Markers Associated With Occupational Exposure to Trichloroethylene

Neoplasms | Epidemiology | Industrial Hygiene

China
National Cancer Institute (NCI)

Completed

Sun Exposure and Melanoma in Agricultural Workers

Melanoma

United States
National Cancer Institute (NCI)

Completed

Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Extended Follow-up of Columbia, MO Serum Bank Participants

Breast Cancer | Ovarian Cancer | Endometrial Cancer

United States
National Cancer Institute (NCI)

Terminated

Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery

Neuroendocrine Tumors | Carcinoma, Neuroendocrine | Neuroendocrine Carcinoma | Neuroendocrine Neoplasms | Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas

United States
National Cancer Institute (NCI)

Completed

A Case-Control Study of Testicular Germ Cell Tumors Among U.S. Military Servicemen

Testicular Cancer

United States
National Cancer Institute (NCI)

Terminated

BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment

Ovarian Cancer

United States
National Cancer Institute (NCI)

Completed

Genetics of Familial Testicular Cancer

Testicular Cancer

United States
National Cancer Institute (NCI)

Completed

Colorectal Neoplasia Screening w Colonoscopy in Asymptomatic Women at Regional Navy/Army Medical Ctrs: The CONCeRN Trial

Colorectal Adenoma

United States
National Cancer Institute (NCI)

Completed

Molecular Staging of Endometrial Cancer

Endometrial Cancer

United States
National Cancer Institute (NCI)

Completed

Refinement of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Via Cognitive Interviewing and Usability Testing

Lymphomas | Leukemias | Multiple Cancers

United States
National Cancer Institute (NCI)

Withdrawn

E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia

Cervical Intraepithelial Neoplasia

United States
National Cancer Institute (NCI)

Completed

Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Cigarette Smoking and Oral Microbiota

Lung Cancer | Oral Cancer | Microbiota

United States
National Cancer Institute (NCI)

Completed

Genetic Epidemiology of Lung Cancer and Smoking

Lung Cancer

Italy
National Cancer Institute (NCI)

Completed

Genes Involved in Resistance or Susceptibility to Hepatitis B Virus

Hepatitis, Viral, Human

China

Clinical Trials Sponsored by Guiyang Public Health Clinical Center

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations